Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer

Maturitas

Volumn 69, Issue 4, 2011, Pages 296-303

  Thara, Eddie ^a   Dorff, Tanya B ^a,b   Pinski, Jacek K ^a,b   Quinn, David I ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Immunotherapy; Prostate; Sipuleucel T (Provenge)

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; DOCETAXEL; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYBRID PROTEIN; NILUTAMIDE; PA 2024; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF; PROVENGE; UNCLASSIFIED DRUG;

ASTHENIA; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOXIA; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE REACTION; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VOMITING;

CANCER VACCINES; DENDRITIC CELLS; DISEASE PROGRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ACTIVE; KAPLAN-MEIER ESTIMATE; MALE; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; TISSUE EXTRACTS;

EID: 79959949897     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.04.012     Document Type: Review

References (37)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 60 5 2010 277 300
2. M.A. Eisenberger, B.A. Blumenstein, and E.D. Crawford Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 15 1998 1036 1042 (Pubitemid 28457865)
3. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520 (Pubitemid 39315318)
4. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512 (Pubitemid 39315317)
5. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 2008 242 245
6. M.J. Moore, D. Osoba, and K. Murphy Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer J Clin Oncol 12 4 1994 689 694 (Pubitemid 24110906)
7. F. Pijpers, R. Faint, and N. Saini Therapeutic cancer vaccines Nat Rev Drug Discov 4 8 2005 623 624 (Pubitemid 41149749)
8. N.J. Nesslinger, R.A. Sahota, and B. Stone Standard treatments induce antigen-specific immune responses in prostate cancer Clin Cancer Res 13 5 2007 1493 1502 (Pubitemid 46450440)
9. R.A. Madan, and J.L. Gulley The current and emerging role of immunotherapy in prostate cancer Clin Genitourin Cancer 8 1 2010 10 16
10. B.I. Rini, L. Fong, and V. Weinberg Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor J Urol 175 6 2006 2087 2091 (Pubitemid 43668588)
11. F. Sallusto, and A. Lanzavecchia Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med 179 4 1994 1109 1118
12. C. Klein, H. Bueler, and R.C. Mulligan Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines J Exp Med 191 10 2000 1699 1708 (Pubitemid 30331568)
13. E.J. Small, D.M. Reese, and B. Um Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor Clin Cancer Res 5 7 1999 1738 1744 (Pubitemid 29334454)
14. P.A. Burch, G.A. Croghan, and D.A. Gastineau Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial Prostate 60 3 2004 197 204 (Pubitemid 38971831)
15. E.J. Small, P. Fratesi, and D.M. Reese Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 23 2000 3894 3903
16. P.A. Burch, J.K. Breen, and J.C. Buckner Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer Clin Cancer Res 6 6 2000 2175 2182 (Pubitemid 30399182)
17. G. Beinart, B.I. Rini, V. Weinberg, and E.J. Small Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer Clin Prostate Cancer 4 1 2005 55 60 (Pubitemid 41018184)
18. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 2006 3089 3094 (Pubitemid 46638945)
19. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 16 2009 3670 3679
20. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
21. United States Food and Drug Administration package insert. 2010 [cited 2011 January 2nd]; Available from: http://www.fda.gov/downloads/ BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031. pdf.
22. P. Schellhammer, C. Higano, and E. Berger A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) AUA Annual Meeting 2009
23. J.W. Simons, E.M. Jaffee, and C.E. Weber Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 10
24. J.W. Simons, B. Mikhak, and J.-F. Chang Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 9
25. S.F. Slovin Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome Clin Adv Hematol Oncol 5 12 2007 972 980
26. E. Small, T. Demkow, and W.R. Gerritsen A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) (abstract) ASCO Genitourinary Cancers Symposium 2009
27. J.P. Eder, P.W. Kantoff, and K. Roper A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer Clin Cancer Res 6 5 2000 1632 1638 (Pubitemid 30305054)
28. H.L. Kaufman, W. Wang, and J. Manola Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group J Clin Oncol 22 11 2004 2122 2132 (Pubitemid 41095145)
29. P.W. Kantoff, T.J. Schuetz, and B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 7 2010 1099 1105
30. P.M. Arlen, J.L. Gulley, and C. Parker A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clin Cancer Res 12 4 2006 1260 1269 (Pubitemid 43342517)
31. R.A. Madan, J.L. Gulley, and J. Schlom Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin Cancer Res 14 14 2008 4526 4531
32. Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer. ClinicalTrials.gov, Bethesda, MD; 2011 [cited 2011 January 2]; Available from: http://clinicaltrials.gov/ct2/show/NCT00450463?term= prostvac&rank=1.
33. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC) T.M. Beer, G.T. Bernstein, and J.M. Corman ASCO Annual Meeting Part I J Clin Oncol 2007
34. Open label study of sipuleucel-T. ClinicalTrials.gov, Bethesda, MD; 2010 [cited 2011 January 2nd]; Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00901342?term=dendreon&rank=5.
35. To evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen. ClinicalTrials.gov, Bethesda, MD; 2010; 2010 [cited 2011 January 2]; Available from: http://clinicaltrials.gov/ct2/show/NCT00715078.
36. Sipuleucel-T as neoadjuvant treatment in prostate cancer. ClinicalTrials.gov, Bethesda, MD; 2010; 2010 [cited 2011 January 2].
37. Provenge (TM) for the treatment of hormone sensitive prostate cancer. ClinicalTrials.gov, Bethesda, MD; 2010 [cited 2011 January 2]; Available from: http://clinicaltrials.gov/ct2/show/NCT00779402?term= Provenge+%28TM%29+for+the+treatment+of+hormone+sensitive+prostate+cancer. &rank=1.